Small nucleic acid drugs, such as siRNA, anti-sense oligonucleotides (ASO), miRNA and aptamers, function by binding to and inhibit the activity of RNA through a process known as RNA interference (RNAi).
This class of molecules offer many advantages over traditional pharmaceuticals: unlimited target selection, high specificity, long half-life, ease of design and fast development and production processes.
In this webinar, the expert speaker will discuss recent advances in the development of small nucleic acid drugs and explain how a one-stop solution from design and synthesis to analysis, screening, verification and delivery can accelerate research.
The key topics will include:
- The different modalities of small nucleic acid drugs and their latest advances
- The major challenges in the development of small nucleic acid drugs and how they are being solved
- Case studies demonstrating the advantages in obtaining candidates having high knockdown efficiency
Register for this webinar today to explore the latest breakthroughs in small nucleic acid drug development.
Speaker
Mark Shulewitz, PhD, Field Application Scientist – Life Science Group, GenScript Biotech Corporation
Dr. Mark Shulewitz earned a PhD from the University of California, Berkeley, and is an expert in Molecular Biology with publications in journals such as Oncogene. He has held key roles in the R&D and commercial teams of leading biotechnology companies, including Genentech, Inc., PDL BioPharma, Inc. and Bio-Rad, Inc.
Mark possesses extensive experience with siRNA, particularly in developing cell-based assays for antibody discovery, development and validation. He has successfully developed and launched numerous products for Life Science Research.
At GenScript, Mark brings his deep experience as a bench scientist to his role as a Field Application Scientist, where he successfully provided technical consultation for multiple siRNA projects, supporting their efficient progress.
Message PresenterWho Should Attend?
This webinar will appeal to those working in the following areas or having the following job titles:
- Beginners and experts interested in RNAi (especially siRNA and ASO) applications
- Those working in universities, research institutes, hospital/medical centers, biotech and biopharma companies
- Students/Researchers interested in the use of RNAi technology for research
- Academic Researchers/Laboratory Directors currently in the field of RNAi research
- Research Scientists/Senior Scientists/Project Leaders from the R&D department who are involved in RNAi projects and want to learn more
What You Will Learn
Attendees will learn about:
- An introduction to the mechanisms, delivery strategies and key differences of several small nucleic acid drugs
- The basic process, key challenges and solutions in developing small nucleic acid drugs
- An understanding of small nucleic acid drugs service and how it can accelerate research
Xtalks Partner
GenScript
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account